The use of lanreotide autogel® in the treatment of intestinal obstruction in a patient with adenocarcinoma

Abstract

Intestinal obstruction is a common complication in patients with advanced abdominal or pelvic cancer.

The synthetic somatostatin analogue octreotide can help relieve nausea, vomiting and pain in patients with inoperable obstruction.

Here, we report a case of recurrent intestinal obstruction in a patient with adenocarcinoma.

Although the obstruction was resolved after 3 days of treatment with octreotide, new episodes of obstruction occurred, resulting in a delay of the chemotherapy treatment.

After 3 episodes of obstruction, we initiated treatment with a longer-acting somatostatin analogue, lanreotide Autogel® 120 mg, administered once every 4 weeks.

The treatment with lanreotide Autogel is being continued, allowing for continuation of the chemotherapy without further episodes of intestinal subocclusion or obstruction.

Until November 2013, the patient received eighteen 4-weekly injections of lanreotide Autogel and did not report side effects.

This case report demonstrates the successful treatment of intestinal obstruction with lanreotide Autogel in a patient with adenocarcinoma.

About this publication.

See also Somatostatin in oncology, the overlooked evidences.